Enrollment open • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD68 (CD68 Molecule)
|
Rituxan (rituximab) • Loqtorzi (toripalimab-tpzi) • Enweida (envafolimab) • LM-101